Robert M. Hershberg's Insider Trades & SAST Disclosures
Robert M. Hershberg's most recent trade in Adaptive Biotechnologies Corp was a trade of 53,000 Common Stock done at an average price of $7.6 . Disclosure was reported to the exchange on March 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert M. Hershberg.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 7.59 per share. | 12 Mar 2025 | 53,000 | 69,690 (0%) | 0% | 7.6 | 402,270 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 23,726 | 23,726 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 15,394 | 122,690 (0%) | 0% | 0 | Common Stock | |
| HilleVax Inc | Robert M. Hershberg | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 1.89 per share. | 04 Feb 2025 | 14,634 | 1,113,399 | - | 1.9 | 27,658 | Common Stock |
| HilleVax Inc | Robert M. Hershberg | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 1.76 per share. | 04 Feb 2025 | 11,901 | 1,101,498 | - | 1.8 | 21,003 | Common Stock |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 26,193 | 26,193 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 13,097 | 51,716 | - | 0 | Class A Common Stock | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 48,044 | 48,044 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 31,328 | 107,296 (0%) | 0% | 0 | Common Stock | |
| HilleVax Inc | Hershberg Robert M. | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 226,885 | 226,885 | - | - | Stock Option (Right to Buy) | |
| HilleVax Inc | M. Robert Hershberg | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 174,202 | 1,128,033 | - | 0 | Common Stock | |
| HilleVax Inc | Hershberg Robert M. | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 14.93 per share. | 08 Feb 2024 | 11,597 | 953,831 | - | 14.9 | 173,161 | Common Stock |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 25,224 | 25,224 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 12,612 | 38,619 | - | 0 | Class A Common Stock | |
| Fate Therapeutics Inc | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 23,329 | 23,329 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 14,775 | 75,968 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 53,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 02 Feb 2023 | 53,000 | 61,193 (0%) | 0% | 0.5 | 23,850 | Common Stock |
| HilleVax Inc | Robert M. Hershberg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 381,950 | 381,950 | - | - | Stock Option (Right to Buy) | |
| HilleVax Inc | Robert M. Hershberg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 187,966 | 965,428 | - | 0 | Common Stock | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 36,290 | 36,290 | - | - | Stock Option (right to buy) | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 18,145 | 26,007 | - | 0 | Class A Common Stock | |
| Fate Therapeutics Inc | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,893 | 11,893 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,650 | 10,659 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 03 Jun 2022 | 672 | 2,009 (0%) | 0% | 22.8 | 15,288 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2022 | 3,306 | 10,716 (0%) | 0% | - | Common Stock | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2022 | 3,306 | 584 | - | - | Common Stock | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 693 | 7,862 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 572 | 7,169 | - | 0 | Class A Common Stock | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 347 | 6,597 | - | 0 | Class A Common Stock | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 5,520 | 0 | - | - | Common Stock | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2021 | 5,520 | 7,410 (0%) | 0% | - | Common Stock | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 3,890 | 3,890 | - | - | Common Stock | |
| Fate Therapeutics Inc | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,334 | 4,334 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,681 | 2,681 (0%) | 0% | 0 | Common Stock | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | 20 Apr 2021 | 525,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | 20 Apr 2021 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) | ||
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | 20 Apr 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | ||
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | 20 Apr 2021 | 12,500 | 0 | - | - | Stock Option (Right to Buy) | ||
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | 20 Apr 2021 | 6,250 | 0 | - | 0 | Common Stock | ||
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | 20 Apr 2021 | 6,250 | 6,250 | - | 0 | Class A Common Stock | ||
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Recursion Pharmaceuticals ... | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 6,250 | 6,250 | - | 0 | Common Stock | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2021 | 144 | 7,684 | - | - | Stock Option (right to buy) | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.71 per share. | 15 Apr 2021 | 144 | 2,034 (0%) | 0% | 14.7 | 2,118 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 74.20 per share. | 15 Apr 2021 | 118 | 1,890 (0%) | 0% | 74.2 | 8,756 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 72.89 per share. | 15 Apr 2021 | 19 | 2,008 (0%) | 0% | 72.9 | 1,385 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 71.71 per share. | 15 Apr 2021 | 7 | 2,027 (0%) | 0% | 71.7 | 502 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.20 per share. | 15 Mar 2021 | 1,500 | 3,390 (0%) | 0% | 11.2 | 16,800 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 1,500 | 0 | - | - | Stock Option (right to buy) | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 67.16 per share. | 15 Mar 2021 | 1,214 | 1,890 (0%) | 0% | 67.2 | 81,532 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 66.03 per share. | 15 Mar 2021 | 282 | 3,104 (0%) | 0% | 66.0 | 18,620 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 63.50 per share. | 15 Mar 2021 | 4 | 3,386 (0%) | 0% | 63.5 | 254 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 44.56 per share. | 08 Mar 2021 | 2,000 | 1,504 (0%) | 0% | 44.6 | 89,120 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 08 Mar 2021 | 2,000 | 3,504 (0%) | 0% | 0.5 | 900 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 2,000 | 53,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 44.56 per share. | 08 Mar 2021 | 2,000 | 0 (0%) | 0% | 44.6 | 89,120 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 08 Mar 2021 | 2,000 | 2,000 (0%) | 0% | 0.5 | 900 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2021 | 2,000 | 53,000 | - | - | Stock Option (Right to Buy) | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.20 per share. | 16 Feb 2021 | 1,188 | 3,078 (0%) | 0% | 11.2 | 13,306 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 1,188 | 1,500 | - | - | Stock Option (right to buy) | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 79.53 per share. | 16 Feb 2021 | 323 | 2,437 (0%) | 0% | 79.5 | 25,688 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 78.40 per share. | 16 Feb 2021 | 318 | 2,760 (0%) | 0% | 78.4 | 24,931 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 82.83 per share. | 16 Feb 2021 | 163 | 1,959 (0%) | 0% | 82.8 | 13,501 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 80.55 per share. | 16 Feb 2021 | 159 | 2,278 (0%) | 0% | 80.5 | 12,807 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 81.79 per share. | 16 Feb 2021 | 156 | 2,122 (0%) | 0% | 81.8 | 12,759 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 83.93 per share. | 16 Feb 2021 | 69 | 1,890 (0%) | 0% | 83.9 | 5,791 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2021 | 3,759 | 3,759 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 14 Feb 2021 | 2,000 | 3,504 (0%) | 0% | 0.5 | 900 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2021 | 2,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 65.45 per share. | 14 Feb 2021 | 2,000 | 1,504 (0%) | 0% | 65.5 | 130,900 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2021 | 1,504 | 1,504 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 2,000 | 57,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 15 Jan 2021 | 2,000 | 2,000 (0%) | 0% | 0.5 | 900 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.20 per share. | 15 Jan 2021 | 1,500 | 3,390 (0%) | 0% | 11.2 | 16,800 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 1,500 | 2,688 | - | - | Stock Option (right to buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 66.34 per share. | 15 Jan 2021 | 1,378 | 622 (0%) | 0% | 66.3 | 91,417 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 71.77 per share. | 15 Jan 2021 | 709 | 2,681 (0%) | 0% | 71.8 | 50,885 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 67.05 per share. | 15 Jan 2021 | 622 | 0 (0%) | 0% | 67.0 | 41,705 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 72.91 per share. | 15 Jan 2021 | 410 | 2,271 (0%) | 0% | 72.9 | 29,893 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 73.66 per share. | 15 Jan 2021 | 291 | 1,980 (0%) | 0% | 73.7 | 21,435 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 74.56 per share. | 15 Jan 2021 | 90 | 1,890 (0%) | 0% | 74.6 | 6,710 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 15 Dec 2020 | 2,000 | 2,000 (0%) | 0% | 0.5 | 900 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 2,000 | 59,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 55.78 per share. | 15 Dec 2020 | 1,759 | 241 (0%) | 0% | 55.8 | 98,117 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.20 per share. | 15 Dec 2020 | 1,500 | 3,390 (0%) | 0% | 11.2 | 16,800 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 1,500 | 4,188 | - | - | Stock Option (right to buy) | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 69.88 per share. | 15 Dec 2020 | 812 | 1,890 (0%) | 0% | 69.9 | 56,743 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 68.68 per share. | 15 Dec 2020 | 688 | 2,702 (0%) | 0% | 68.7 | 47,252 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 57.01 per share. | 15 Dec 2020 | 241 | 0 (0%) | 0% | 57.0 | 13,739 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 2,000 | 61,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 16 Nov 2020 | 2,000 | 2,000 (0%) | 0% | 0.5 | 900 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 47.60 per share. | 16 Nov 2020 | 1,777 | 223 (0%) | 0% | 47.6 | 84,585 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 1,500 | 5,688 | - | - | Stock Option (right to buy) | |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.20 per share. | 16 Nov 2020 | 1,500 | 3,390 (0%) | 0% | 11.2 | 16,800 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 46.31 per share. | 16 Nov 2020 | 754 | 2,636 (0%) | 0% | 46.3 | 34,918 | Common Stock |
| Nanostring Technologies Inc | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 47.03 per share. | 16 Nov 2020 | 746 | 1,890 (0%) | 0% | 47.0 | 35,084 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Sale of securities on an exchange or to another person at price $ 48.41 per share. | 16 Nov 2020 | 223 | 0 (0%) | 0% | 48.4 | 10,795 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.45 per share. | 15 Oct 2020 | 2,000 | 2,000 (0%) | 0% | 0.5 | 900 | Common Stock |
| Adaptive Biotechnologies Corp | Robert M. Hershberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2020 | 2,000 | 63,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges